深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2025-039 深圳市理邦精密仪器股份有限公司 一、《公司章程》主要修订情况 根据《中华人民共和国公司法》《关于新〈公司法〉配套制度规则实施相关 过渡期安排》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作》等法律法规及规范性文件的 相关规定，公司拟将《公司章程》中相关条款、其他相关制度中有关监事、监事 会相关的表述及条款进行相应修订，本次《公司章程》修订完成后，公司将不再 设置监事会，公司《监事会议事规则（2025 年 4 月）》等监事会相关制度相应废 止，监事会的职权由董事会审计委员会行使。 本次修订后的《公司章程》《章程修订对照表》以及其他公司治理制度详见 公司同日于巨潮资讯网（www.cninfo.com.cn）披露的相关公告。 二、公司部分治理制度的修订及新增情况 为全面贯彻落实最新法律法规要求，确保公司治理与监管规定保持同步，进 一步规范公司运作机制，提升公司治理水平，根据《中华人民共和国公司法》《关 于新〈公司法〉配套制度规则实施相关过渡期安排》《 ...

2025 年第一次临时股东会的通知 关于召开 证券代码：300206 证券简称：理邦仪器 公告编号：2025-038 深圳市理邦精密仪器股份有限公司 关于召开 2025 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》及有关法律、法规和《公司 章程》等相关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 13 日 15:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 13 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投 票的具体时间为 2025 年 11 月 13 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2025 年 11 月 06 日 7、出席对象： （1）截至 2025 年 11 月 6 ...

深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2025-037 深圳市理邦精密仪器股份有限公司 第六届监事会 2025年第三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）第六届监事会 2025 年第三次会议于 2025 年 10 月 27 日（星期一）11:30 在深圳市坪山区坑梓街道金 沙社区金辉路 15 号理邦仪器工业园会议室召开，会议通知于 2025 年 10 月 21 日以电子邮件方式发出。会议应出席监事 3 名，实际出席监事 3 名。本次会议召 开符合《公司法》及《公司章程》的相关规定。会议由监事会主席周纯女士主持， 出席会议的监事审议并通过记名投票方式表决通过了如下决议： 1、审议通过《2025 年第三季度报告》的议案 经审核，监事会认为：董事会编制和审议公司《2025 年第三季度报告》的 程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反 映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。具体内 容详见公司 ...

证券代码：300206 证券简称：理邦仪器 公告编号：2025-036 深圳市理邦精密仪器股份有限公司 深圳市理邦精密仪器股份有限公司 第六届董事会 2025年第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）第六届董事会 2025 年第三次会议于 2025 年 10 月 27 日（星期一）10:00 在深圳市坪山区坑梓街道金 沙社区金辉路 15 号理邦仪器工业园会议室召开，会议通知于 2025 年 10 月 21 日以电子邮件方式发出。会议应出席董事 7 名，实际出席董事 7 名。本次会议召 开符合《公司法》及《公司章程》的相关规定。会议由董事长张浩先生主持，出 席会议的董事审议并通过记名投票方式表决通过了如下决议： 1、审议通过《2025 年第三季度报告》的议案 经审核，董事会认为公司编制的《2025 年第三季度报告》真实、准确、完 整，不存在任何虚假记载、误导性陈述或者重大遗漏。具体内容详见公司同日于 巨潮资讯网（www.cninfo.com.cn） 披露的相关公告。 公司董事会审计委员 ...

理邦仪器公告，第三季度营收为5.32亿元，同比增长15.72%；净利润为1.02亿元，同比增长118.28%。 前三季度营收为14.46亿元，同比增长4.63%；净利润为2.57亿元，同比增长49.29%。 ...

深圳市理邦精密仪器股份有限公司 2025 年第三季度报告 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第三季度财务会计报告是否经过审计 □是 否 证券代码：300206 证券简称：理邦仪器 公告编号：2025-035 深圳市理邦精密仪器股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 532,269,656.86 | 15.72% | 1,446,076,915.63 | ...

Core Viewpoint - The establishment of a localized manufacturing center in San Diego by Shenzhen Lifang Precision Instrument Co., Ltd. marks a significant step towards achieving full localization of its medical instrument products, enhancing its competitiveness in the North American market [2][3]. Group 1: Localization and Market Strategy - The new manufacturing center spans approximately 1,940 square meters and has received MDSAP certification, indicating compliance with international regulatory standards [2]. - This facility will enable Lifang to shorten service response times for North American clients and provide stable instrument supply and localized technical support, particularly in high-end monitoring and diagnostic equipment [2][3]. - The MDSAP certification covers major markets including the US, Canada, Australia, Japan, and the EU, which strengthens Lifang's competitive position in North America and lays the groundwork for future expansion into Asian and European high-end medical instrument markets [2][3]. Group 2: Implications for Procurement and Manufacturing - For scientific instrument purchasers, Lifang's localization means shorter delivery times, lower transportation costs, and more flexible customization services [3]. - Instrument manufacturers are encouraged to accelerate technological iterations to adapt to the restructuring of global supply chains, potentially leading to a new model of "local production + global collaboration" in the medical device industry [3]. Group 3: Company Overview and R&D Investment - Lifang focuses on innovation and clinical proximity, covering six major business segments: patient monitoring, ECG diagnosis, women's health, in vitro diagnostics, ultrasound imaging, and smart health [4]. - In 2024, the company's R&D investment is projected to account for 18.55% of its revenue, with cumulative R&D spending exceeding 2.71 billion since its listing in 2011, establishing strong partnerships with over 50,000 medical institutions [4].

Core Insights - The company, Libang Instruments, reported that as of September 30, 2025, the number of shareholders is 22,710 [1] Summary by Categories Company Information - Libang Instruments has a projected shareholder count of 22,710 by September 30, 2025 [1]

Core Viewpoint - The introduction of handheld ultrasound technology is set to revolutionize maternal safety in Africa, allowing for early detection of pregnancy complications and reducing the need for long-distance travel to medical facilities [1][3]. Group 1: Technology and Innovation - The World Health Organization (WHO) recommends that pregnant women undergo an ultrasound scan before 24 weeks of pregnancy to estimate gestational age and identify potential fetal abnormalities [1]. - Handheld ultrasound devices, which are portable and user-friendly, are being developed to address the lack of access to traditional ultrasound services in many African countries [1][6]. - Chinese companies are entering the African market with these innovative products, aiming to improve maternal healthcare [1][8]. Group 2: Market Dynamics - In 2023, over 700 women die daily from preventable pregnancy and childbirth complications, with 70% of these deaths occurring in sub-Saharan Africa [3]. - The market for medical devices in Africa is characterized by a large population base, which presents significant opportunities despite lower purchasing power [7][8]. - Chinese medical devices are favored in Africa for their solid basic functionality and stable quality, despite competition from lower-priced Indian products [8]. Group 3: Implementation Challenges - The introduction of medical devices in Africa requires not only the equipment but also adequate training for healthcare workers to ensure effective usage [9][10]. - WHO statistics indicate that 50% to 80% of medical equipment in developing countries is not functioning properly due to lack of management and maintenance [9]. - Successful implementation of new technologies hinges on regular and effective training programs for healthcare professionals [9][11].

Core Insights - The establishment of a local manufacturing center in San Diego, California, marks a significant step for the company in localizing production in the U.S. [1] - The new facility, covering an area of 20,882 square feet (approximately 1,940 square meters), aims to enhance supply chain resilience and overall service capabilities in North America [1] - The center has already received MDSAP certification and California FDB medical device production license, indicating compliance with regulatory standards [1] Group 1 - The company has been operating in the U.S. market for 15 years, developing a comprehensive market penetration and customer service network [1] - The new manufacturing center will leverage the existing marketing network to extend upstream and downstream capabilities, aiming to meet the growing medical demands in North America more effectively [1] - The president of the company emphasized the commitment to user proximity and clinical service, aiming for faster market response and product innovation tailored to local needs [1][3] Group 2 - The opening ceremony coincided with the company's 30th anniversary and the 15th anniversary of its U.S. subsidiary, highlighting its long-term commitment to the region [3] - The San Diego region is recognized for its strong life sciences industry cluster, providing a favorable environment for business development and talent support [3] - The company aims to continuously improve its global supply chain service system to create sustainable competitive advantages in the North American and global medical markets [5]